I
Innovative Cellular Therapeutics
A Shanghai-based biotechnology company engaged in research and development of cell therapy
About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics (ICT) is a clinical-stage biotechnology firm focused on developing cellular immunotherapies for solid tumors. The company was co-founded in 2009 by Dr. Larry (Lei) Xiao, who serves as Chairman, CEO, and CSO, and Dr. Zoe Zhao Wu, who is the President. Dr. Xiao brings over two decades of experience in stem cells, cell therapy, and gene editing, with a Ph.D. from Munich University and postdoctoral work at Johns Hopkins. His academic career includes professorships where he specialized in stem cell research, providing a strong scientific foundation for ICT's endeavors.
The company initially focused on induced pluripotent stem cells (iPSC) before pivoting to CAR-T cell technology. A significant milestone was achieved in 2015 when its first CAR-T product for Acute Lymphoblastic Leukemia demonstrated an 85% complete response rate in a 39-patient trial. This early success in liquid tumors informed the development of its solid tumor platform. By 2018, ICT established U.S. operations, opening its global headquarters in Rockville, MD, in 2019 to concentrate on the American market. As a venture-backed entity, ICT has successfully raised capital to advance its pipeline, with investors including CDH, LH Ventures, and SB China Venture Capital.
ICT's business model is centered on the research, development, and eventual commercialization of its CAR-T therapies. The company is currently pre-revenue, investing its capital into clinical trials to gain regulatory approval. The core of its therapeutic strategy is the proprietary CoupledCAR® technology platform. This platform is engineered to overcome the challenges of treating solid tumors by promoting the expansion and persistence of CAR-T cells within the body, enhancing their ability to infiltrate tumors and resist the immunosuppressive tumor microenvironment. This enables the engineered T-cells to effectively target and kill cancer cells.
The lead product candidate, GCC19CART, targets relapsed or refractory metastatic colorectal cancer (mCRC). Clinical trials for GCC19CART have shown promising results in both the U.S. and China. In a U.S. Phase 1 trial, an objective response rate of 80% was observed at a specific dosage level. The U.S. FDA granted Fast Track designation to GCC19CART in April 2022, potentially accelerating its path to market. Beyond colorectal cancer, ICT is advancing a pipeline of other CAR-T candidates for solid tumors, including thyroid and prostate cancer.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Rockville, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 46.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Market Intelligence, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2021 | $40M | $160M | CDH Investments | — |
| SERIES COther financing | Dec 2019 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Innovative Cellular Therapeutics is 3.4K monthly website visits, up 161.5% over the last three months. Innovative Cellular Therapeutics's team grew 15.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Innovative Cellular Therapeutics in the Rockville ecosystem
The Innovative Cellular Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Innovative Cellular Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innovative Cellular Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









